Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study

Abstract

In SBPC patients, apatinib at less than 500 mg daily dose as mono-therapy had tolerable toxicity. Apatinib at dose of 250 mg daily in combining with RT synergized pain control, the overall AEs were manageable. Further studies are needed in large sample size future trials.